Dynamic profile of the HBeAg-anti-HBe system in acute and chronic hepatitis B virus infection: A clinical-laboratory approach

Pondé, Robério Amorim de Almeida

doi:10.1007/s11033-020-06056-4

Cited by 11 publications

(3 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A positive e antibody suggests that the patient is less infectious or in remission. Although there are some cases with e antibody positive results yet their disease persists, most typically owing to infection with a mutant hepatitis B virus [ 36 , 37 ]. HBcAg is generally not detectable in the serum, while HBcAb can be detected.…”

Section: Discussionmentioning

confidence: 99%

Application Effect and Accuracy Analysis of Electrochemiluminescence Immunoassay and Enzyme-Linked Immunosorbent Assay in the Serological Test of Hepatitis B Virus

Lian

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. To explore the validity and accuracy of electrochemiluminescence immunoassay (ECLIA) and enzyme-linked immunosorbent assay (ELISA) in the serological detection of the hepatitis B virus. Methods. From 6 February 2019 to 1 March 2020, 96 patients diagnosed with hepatitis B virus infection in our hospital were recruited and assigned at a ratio of 1 : 1 to experimental groups A (GA) and B (GB), with 48 cases in each group, and the five major serological indicators of hepatitis B were tested and analyzed using ECLIA and ELISA. In addition, 50 suspected patients were selected for two tests, respectively, to compare the accuracy of the two test methods. Results. ECLIA was associated with significantly higher expression levels and higher detection rates of HBeAg, HBeAb, HBsAg, and HBsAb versus ELISA ( P < 0.05 ), and the difference in the expression and detection rates of HBcAb levels between the two groups did not come up to the statistical standard ( P > 0.05 ). ECLIA yielded significantly higher sensitivity and specificity than ELISA ( P < 0.05 ), while the two methods showed comparable detection accuracy ( P > 0.05 ). Conclusion. Despite the inconsistent results of the latest studies on the serological detection of hepatitis B by the two techniques, ECLIA is consistently superior to ELISA and provides better diagnostic benefits and merits promotion.

show abstract

Section: Discussionmentioning

confidence: 99%

Application Effect and Accuracy Analysis of Electrochemiluminescence Immunoassay and Enzyme-Linked Immunosorbent Assay in the Serological Test of Hepatitis B Virus

Lian

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…By contrast, the nondetection of anti-HBe antibodies is related to the "e" antigen concentration being always high, resulting from persistent viral replication, indicating no cellular immune mechanisms to contain the infection, with the consequent evolution of the infection to chronicity. 64 However, it is important to note that anti-HBe antibodies may not be detected in all HBV-infected patients who progress to recovery, or may appear several months or years after the anti-HBc detection, as mentioned earlier. 60,65 Factors related to the "e" antigen low immunogenicity have been considered as one of the probable causes.…”

Section: Significance Of Detection Of Anti-hbe Antibodies After Acute Infectionmentioning

confidence: 94%

Detection of the serological markers hepatitis B virus surface antigen (HBsAg) and hepatitis B core IgM antibody (anti‐HBcIgM) in the diagnosis of acute hepatitis B virus infection after recent exposure

Pondé

2021

Microbiology and Immunology

Self Cite

View full text Add to dashboard Cite

The serological diagnosis of acute hepatitis B virus (HBV) infection after recent exposure has been established by the hepatitis B virus surface antigen (HBsAg) and anti-hepatitis B core IgM antibody (anti-HBcIgM) detection in serum, sometimes accompanied by the detection of hepatitis B "e" antigen (HBeAg). Despite this characteristic serological profile, misdiagnosis can occur in cases of unexpected or atypical behavior of the serological markers in the bloodstream, or if the true meaning of its expression is not properly investigated, or even if there is a possibility of interference from factors not necessarily linked to the infectious process, in the detection of these markers. This review discusses the influence of these variables on laboratory results for these two serological markers and, therefore, the potential risk of these variables compromising the correct diagnosis of acute infection after recent HBV exposure.

show abstract

“…HBeAg is a marker of active viral infection, such that seroconversion to anti-HBe antibody positivity results in inactive disease, with normalized liver enzyme levels and decreased HBV DNA levels [ 10 ]. However, viral activity and ALT fluctuations persist within the HBeAg-negative chronic hepatitis phase of infection due to genomic mutations altering HBeAg expression [ 11 ]. Quantified HBeAg levels have also been shown in the literature to be associated with HBeAg seroconversion and pegylated-interferon α (peg-IFN) and nucleos(t)ide analogue (NA) treatment response [ 12 , 13 , 14 , 15 ].…”

Section: Traditional Hbv Diagnostic Testingmentioning

confidence: 99%

Novel Biomarkers of Hepatitis B Virus and Their Use in Chronic Hepatitis B Patient Management

Osiowy

2021

Viruses

View full text Add to dashboard Cite

Even though an approved vaccine for hepatitis B virus (HBV) is available and widely used, over 257 million individuals worldwide are living with chronic hepatitis B (CHB) who require monitoring of treatment response, viral activity, and disease progression to reduce their risk of HBV-related liver disease. There is currently a lack of predictive markers to guide clinical management and to allow treatment cessation with reduced risk of viral reactivation. Novel HBV biomarkers are in development in an effort to improve the management of people living with CHB, to predict disease outcomes of CHB, and further understand the natural history of HBV. This review focuses on novel HBV biomarkers and their use in the clinical setting, including the description of and methodology for quantification of serum HBV RNA, hepatitis B core-related antigen (HBcrAg), quantitative hepatitis B surface antigen (qHBsAg), including ultrasensitive HBsAg detection, quantitative anti-hepatitis B core antigen (qAHBc), and detection of HBV nucleic acid-related antigen (HBV-NRAg). The utility of these biomarkers in treatment-naïve and treated CHB patients in several clinical situations is further discussed. Novel HBV biomarkers have been observed to provide critical clinical information and show promise for improving patient management and our understanding of the natural history of HBV.

show abstract

Dynamic profile of the HBeAg-anti-HBe system in acute and chronic hepatitis B virus infection: A clinical-laboratory approach

Cited by 11 publications

References 83 publications

Application Effect and Accuracy Analysis of Electrochemiluminescence Immunoassay and Enzyme-Linked Immunosorbent Assay in the Serological Test of Hepatitis B Virus

Application Effect and Accuracy Analysis of Electrochemiluminescence Immunoassay and Enzyme-Linked Immunosorbent Assay in the Serological Test of Hepatitis B Virus

Detection of the serological markers hepatitis B virus surface antigen (HBsAg) and hepatitis B core IgM antibody (anti‐HBcIgM) in the diagnosis of acute hepatitis B virus infection after recent exposure

Novel Biomarkers of Hepatitis B Virus and Their Use in Chronic Hepatitis B Patient Management

Contact Info

Product

Resources

About